Morbidity

Percent prevalence of chronic conditions among users of chronic drugs program, 2016*

Chronic conditions	Prevalence
Cardiovascular diseases, atherosclerosis, coagulation problems and hypertension	47%
Diabetes	15%
Ulcers	10%
High cholesterol level	10%
Other diseases (Rheumatism, uric acid, glaucoma, osteoporosis...)	8%
Diseases of the nervous system	3%
Epilepsy	3%
Thyroid Problems	2%
Asthma	2%

*For previous years check the Statistical Bulletins' page

Newly reported HIV cases, 2020

Newly reported HIV cases,2021

Newly reported HIV cases, 2022

New reported HIV cases,2023

New reported HIV cases,2024

https://www.moph.gov.lb/userfiles/files/Prevention/TB%20Program/NTP-NAP%20Annual%20Report-2024.pdf

Number of Measles cases

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Measles	9	1,760	235	39	44	126	952	1070	-	28	95	351

Source :MoPH 01/09/2024

Number of Tuberculosis cases*

Tuberculosis cases	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total number of cases	630	689	682	666	657	632	668	760	656	466	510	510	540
Number of Lebanese cases	330	341	337	312	305	271	254	288	277	233	263	249	225
Number of Non-Lebanese cases	300	348	345	354	352	361	414	472	379	233	247	261	315

*MOPH National Tuberculosis Program 01/05/2025

The trend in Tuberculosis cases by Nationality between 2019 and 2024

...

129

...

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L04AA27	PMS-FINGOLIMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	19,351,580 L.L
L04AA27	SCLEMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	18,264,981 L.L
L04AA27	SCLEMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	17,079,643 L.L
L04AA27	LYXIA	G	Fingolimod Hydrochloride - 0.25mg	0.5mg	Capsule, hard	32,406,715 L.L
L04AA27	SCLEMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	L.L
L04AA27	SCLEMOD	G	Fingolimod Hydrochloride - 0.5mg	0.5mg	Capsule	L.L
L04AA29	XELJANZ	B	Tofacitinib - 5mg	5mg	Tablet	80,685,473 L.L
L04AA29	TOLVAR	G	Tofacitinib - 5mg	5mg	Tablet, film coated	48,411,736 L.L
L04AA29	TRIJAN	G	Tofacitinib - 5mg	5mg	Tablet, film coated	54,863,315 L.L
L04AA29	XELJANZ XR	B	Tofacitinib - 11mg	11mg	Tablet, extended release	78,687,316 L.L
L04AA29	TRIJAN	G	Tofacitinib - 10mg	10mg	Tablet, film coated	84,793,962 L.L
L04AA29	XELJANZ	B	Tofacitinib - 5mg	5mg	Tablet	L.L
L04AA31	AUBAGIO	B	Teriflunomide - 14mg	14mg	Tablet, film coated	38,773,533 L.L
L04AA31	AUBAGIO	B	Teriflunomide - 14mg	14mg	Tablet, film coated	38,773,533 L.L
L04AA31	TERAGIO	G	Teriflunomide - 14mg	14mg	Tablet	49,451,224 L.L
L04AA31	TERAGIO	G	Teriflunomide - 14mg	14mg	Tablet	23,076,914 L.L
L04AA31	TERAGIO	G	Teriflunomide - 14mg	14mg	Tablet	L.L
L04AA32	OTEZLA	B	Apremilast - 4x10mg- 4x20mg- 19x30mg		Tablet, film coated	34,751,325 L.L
L04AA32	APRIVA STARTER PACK	G	Apremilast - 10mg, Apremilast - 20mg, Apremilast - 30mg		Tablet, film coated	22,154,866 L.L
L04AA32	OTEZLA	B	Apremilast - 30mg	30mg	Tablet, film coated	49,829,454 L.L
L04AA32	APRIVA	G	Apremilast - 30mg	30mg	Tablet, film coated	41,455,526 L.L
L04AA33	ENTYVIO	BioTech	Vedolizumab - 300mg	300mg	Injectable powder for concentrate for solution	152,492,033 L.L
L04AA33	ENTYVIO	BioTech	Vedolizumab - 108mg	108mg	Injectable solution	92,478,560 L.L
L04AA33	ENTYVIO	BioTech	Vedolizumab - 108mg	108mg	Injectable solution	92,478,560 L.L
L04AA36	OCREVUS	BioTech	Ocrelizumab - 300mg/10ml	300mg/10ml	Injectable concentrate for solution	547,517,314 L.L
L04AA36	OCREVUS	BioTech	Ocrelizumab - 920mg/23ml	920mg/23ml	Injectable solution	1,095,034,629 L.L
L04AA36	OCREVUS	BioTech	Ocrelizumab - 300mg/10ml	300mg/10ml	Injectable concentrate for solution	L.L
L04AA37	OLUMIANT	B	Baricitinib - 2mg	2mg	Tablet, film coated	68,053,864 L.L
L04AA37	OLUMIANT	B	Baricitinib - 4mg	4mg	Tablet, film coated	68,053,864 L.L
L04AA42	MAYZENT	B	Siponimod - 0.25mg	0.25mg	Tablet, film coated	15,102,158 L.L

...

129

...